Plasmid DNA Manufacturing Technology - Co-Developed By Boehringer Ingelheim Austria With BIA Separations
To meet the growing need for pharmaceutical grade pDNA, Boehringer Ingelheim Austria has developed a high cell density fermentation technology achieving titers up to 1 g pDNA per Liter, and has specifically designed equipment for the automated and gentle lysis of the biomass. A key and novel element of the production process is the use of CIM Convection Interaction Media(R) short monolithic columns for the purification of pDNA. The fast separation speed, outstanding capacity, and excellent separation power of CIM(R) columns, developed by BIA Separations, allows a 15-fold increase in productivity compared to traditional supports. "Our customers clearly benefit from this new development as the process is free of antibiotics, animal-derived raw materials, enzymes and organic solvents and employs the powerful CIM(R) separation technology" says Dr. Kurt Konopitzky, Head of the Division Biopharmaceuticals/Operations at Boehringer Ingelheim Austria.
Boehringer Ingelheim Austria and BIA Separations are committed to developing manufacturing technology that leads to innovative biopharmaceuticals. The process produces pDNA on a large scale and follows Good Manufacturing Practice for clinical and commercial applications.
After successfully co-developing this novel process, the two companies are collaborating on a non-exclusive basis where BIA Separations will supply Boehringer Ingelheim Austria with CIM(R) columns.